Drug Profile
Research programme: adult stem cell therapy - diabetes - Regenetech
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Regenetech
- Developer Johns Hopkins University
- Class Stem cell therapies
- Mechanism of Action Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (Intra-abdominal, Implant)
- 15 Nov 2007 Preclinical trials in Type-1 diabetes mellitus in USA (Intra-abdominal)